Evidence map›Paper›PMID 31308061›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.

Sriram Sundaravel, Wen-Liang Kuo, Jong Jin Jeong, Gaurav S Choudhary, Shanisha Gordon-Mitchell, Hui Liu, Tushar D Bhagat, Kathy L McGraw, Sandeep Gurbuxani, Alan F List and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Long Noncoding RNACancer management and research · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sriram SundaravelSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Wen-Liang KuoSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Jong Jin JeongSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Gaurav S ChoudharyAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.ORCID 0000-0001-5365-6706
Shanisha Gordon-MitchellAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
Hui LiuSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
Tushar D BhagatAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.ORCID 0000-0002-4527-5505
Kathy L McGrawMoffitt Cancer Center, Tampa, Florida.
Sandeep GurbuxaniDepartment of Pathology, The University of Chicago, Chicago, Illinois.
Alan F ListMoffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-1647-2972
Amit VermaAlbert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
Amittha WickremaSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois. awickrema@uchicago.edu.
University of Chicago · USAlbert Einstein College of Medicine · USMoffitt Cancer Center · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
TR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6M
The role of Dock4 in normal and aberrant erythropoiesisR01HL116336 · NHLBI · UNIVERSITY OF CHICAGO · PI VERMA, AMIT K., WICKREMA, AMITTHA · 2012 to 2015
$1.6M
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapyK00CA223044 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SUNDARAVEL, SRIRAM · 2019 to 2022
$379k
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapyF99CA223044 · NCI · UNIVERSITY OF CHICAGO · PI SUNDARAVEL, SRIRAM · 2017 to 2018
$90k
NCI NIH HHS F99 CA223044NCI NIH HHS K00 CA223044NCI NIH HHS P30 CA060553NHLBI NIH HHS R01 HL116336NIGMS NIH HHS P41 GM108569
6 · The paper itself

Abstract

purposeMyelodysplastic syndromes (MDS) with deletion of chromosome 7q/7 [-7/(del)7q MDS] is associated with worse outcomes and needs novel insights into pathogenesis. Reduced expression of signaling protein dedicator of cytokinesis 4 (DOCK4) in patients with -7/(del)7q MDS leads to a block in hematopoietic stem cell (HSC) differentiation. Identification of targetable signaling networks downstream of DOCK4 will provide means to restore hematopoietic differentiation in MDS.

resultsWe demonstrate that reduced levels of DOCK4 lead to increased global tyrosine phosphorylation of proteins in primary human HSCs. LYN kinase and phosphatases INPP5D (SHIP1) and PTPN6 (SHP1) displayed greatest levels of tyrosine phosphorylation when DOCK4 expression levels were reduced using DOCK4-specific siRNA. Our data also found that increased phosphorylation of SHIP1 and SHP1 phosphatases were due to LYN kinase targeting these phosphatases as substrates. Increased migration and impediment of HSC differentiation were consequences of these signaling alterations. Pharmacologic inhibition of SHP1 reversed these functional aberrations in HSCs expressing low DOCK4 levels. In addition, differentiation block seen in DOCK4 haplo-insufficient [-7/(del)7q] MDS was rescued by inhibition of SHP1 phosphatase.

conclusionsLYN kinase and phosphatases SHP1 and SHIP1 are perturbed when DOCK4 expression levels are low. Inhibition of SHP1 promotes erythroid differentiation in healthy HSCs and in -7/(del)7q MDS samples with low DOCK4 expression. Inhibitors of LYN, SHP1 and SHIP1 also abrogated increased migratory properties in HSCs expressing reduced levels of DOCK4.

Indexed as

Loss of Function MutationAntineoplastic AgentsCell MovementGene Expression Regulation, NeoplasticGTPase-Activating ProteinsHematopoietic Stem CellsHumansModels, BiologicalMyelodysplastic SyndromesPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphorylationProtein BindingProtein Tyrosine Phosphatase, Non-Receptor Type 6Signal TransductionAntineoplastic AgentsDOCK4 protein, humanGTPase-Activating ProteinsINPP5D protein, humanPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesProtein Tyrosine Phosphatase, Non-Receptor Type 6

Identifiers

PMID31308061
PMCPMC6744990
OpenAlexW2962157264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.